Condition
Crigler Najjar Syndrome
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01765283Phase 1Completed
Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)
NCT02051049Completed
Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
NCT02302690CompletedPrimary
Immunity Against AAV in Crigler Najjar Patient
NCT02356978Not ApplicableUnknownPrimary
New Phototherapy Device to Treat Patients With Crigler-Najjar Disease
Showing all 4 trials